Copyright
©The Author(s) 2016.
World J Hepatol. Apr 28, 2016; 8(12): 557-565
Published online Apr 28, 2016. doi: 10.4254/wjh.v8.i12.557
Published online Apr 28, 2016. doi: 10.4254/wjh.v8.i12.557
Table 2 Effect of new direct-acting antivirals in pregnancy and Food and Drug Administration Pregnancy Categories
Drug | Embryotoxicity and/or teratogenicity1 | Dose-escalation2 | Transfer across placenta | Transfer into milk | FDA Pregnancy Category3 | |
Sofosbuvir | No | 28-fold | Yes | Yes | B | |
Simeprevir | Yes | 4-fold | Yes | Yes | C | |
Daclatasvir | Yes | 4-fold | Yes | Yes | NA4 | |
Ledipasvir | No | Maternal toxic doses | Yes | Yes | B | |
Viekirax | Ombitasvir | Yes | 4-fold | Minimal | Yes | B |
Paritaprevir | 32-fold | |||||
Ritonavir | 8-fold | |||||
Dasabuvir | No | 48-fold | Minimal | Yes | B |
- Citation: Spera AM, Eldin TK, Tosone G, Orlando R. Antiviral therapy for hepatitis C: Has anything changed for pregnant/lactating women? World J Hepatol 2016; 8(12): 557-565
- URL: https://www.wjgnet.com/1948-5182/full/v8/i12/557.htm
- DOI: https://dx.doi.org/10.4254/wjh.v8.i12.557